NAMS Menopause Certification Success Guide 2026/2027 |
Complete Exam Review, Practice Questions & Detailed
Rationales
Question 1
What is the primary hormonal driver responsible for the rise in serum
follicle-stimulating hormone (FSH) levels during the menopausal
transition?
• A. Decreased inhibin B production from a declining follicular pool
• B. Direct hypersecretion of gonadotropins by the anterior pituitary
gland
• C. Complete cessation of adrenal cortisol synthesis
• D. Increased secretion of anti-Müllerian hormone by theca cells
Correct Answer: A. Decreased inhibin B production from a declining
follicular pool
Detailed Rationale: Inhibin B, produced by growing follicles, exerts
negative feedback on FSH. As the ovarian follicle pool diminishes,
inhibin B levels drop, reducing negative feedback and causing a
compensatory rise in FSH.
Question 2
According to the Stages of Reproductive Aging Workshop (STRAW+10)
criteria, what defines early perimenopause (Stage -4)?
• A. Persistent difference of 7 days or more in the length of
consecutive menstrual cycles
, • B. Amenorrhea lasting for 12 consecutive months
• C. Regular menses accompanied by severe hot flashes and night
sweats
• D. Complete cessation of ovarian function prior to age 40
Correct Answer: A. Persistent difference of 7 days or more in the length
of consecutive menstrual cycles
Detailed Rationale: Early perimenopause is characterized by a
persistent difference of 7 days or more in consecutive cycle lengths due
to fluctuating ovarian function.
Question 3
Which hypothalamic neuronal population is primarily responsible for
generating vasomotor symptoms when deprived of estrogen?
• A. Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
• B. Dopaminergic neurons of the substantia nigra
• C. Oxytocin-secreting paraventricular neurons
• D. Serotonergic neurons of the raphe nucleus exclusively
Correct Answer: A. Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
Detailed Rationale: Estrogen withdrawal leads to hypertrophy and
hyperactivation of KNDy neurons in the infundibular nucleus, narrowing
the thermoneutral zone and triggering inappropriate heat dissipation
responses.
Question 4
,For a postmenopausal woman with an intact uterus, what is the clinical
necessity of adding a progestogen when systemic estrogen is
prescribed?
• A. To prevent endometrial hyperplasia and malignancy caused by
unopposed estrogen stimulation
• B. To prevent all-cause mortality and cardiovascular disease
• C. To increase bone mineral density in the cortical skeleton
• D. To eliminate the need for routine lipid panel surveillance
Correct Answer: A. To prevent endometrial hyperplasia and malignancy
caused by unopposed estrogen stimulation
Detailed Rationale: Unopposed systemic estrogen stimulates
unchecked proliferation of the endometrium, which significantly
increases the risk of hyperplasia and endometrial cancer. Progestogen
induces secretory changes that protect the uterine lining.
Question 5
Which of the following conditions represents an absolute
contraindication to the initiation of systemic menopausal hormone
therapy (MHT)?
• A. Active or history of breast cancer
• B. Controlled essential hypertension
• C. Mild asymptomatic cholelithiasis
• D. Stable treated hypothyroidism
Correct Answer: A. Active or history of breast cancer
, Detailed Rationale: Estrogen-sensitive malignancies, such as breast
cancer, represent absolute contraindications to systemic MHT because
exogenous hormones can stimulate tumor growth or recurrence.
Question 6
Which non-hormonal medication class is commonly utilized as a first-
line therapy for moderate-to-severe vasomotor symptoms when
hormone therapy is contraindicated or declined?
• A. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-
norepinephrine reuptake inhibitors (SNRIs)
• B. Loop and thiazide diuretics
• C. Proton pump inhibitors
• D. H2-receptor antagonists
Correct Answer: A. Selective serotonin reuptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs)
Detailed Rationale: Low-dose SSRIs and SNRIs modulate central
neurotransmitter tone and help reset the thermoneutral zone,
providing safe and effective non-hormonal relief for hot flashes.
Question 7
What clinical term describes the collection of symptoms including
vaginal dryness, dyspareunia, burning, and urinary urgency experienced
during and after the menopausal transition?
• A. Genitourinary syndrome of menopause (GSM)
• B. Premature ovarian insufficiency (POI)
• C. Polycystic ovary syndrome (PCOS)
Complete Exam Review, Practice Questions & Detailed
Rationales
Question 1
What is the primary hormonal driver responsible for the rise in serum
follicle-stimulating hormone (FSH) levels during the menopausal
transition?
• A. Decreased inhibin B production from a declining follicular pool
• B. Direct hypersecretion of gonadotropins by the anterior pituitary
gland
• C. Complete cessation of adrenal cortisol synthesis
• D. Increased secretion of anti-Müllerian hormone by theca cells
Correct Answer: A. Decreased inhibin B production from a declining
follicular pool
Detailed Rationale: Inhibin B, produced by growing follicles, exerts
negative feedback on FSH. As the ovarian follicle pool diminishes,
inhibin B levels drop, reducing negative feedback and causing a
compensatory rise in FSH.
Question 2
According to the Stages of Reproductive Aging Workshop (STRAW+10)
criteria, what defines early perimenopause (Stage -4)?
• A. Persistent difference of 7 days or more in the length of
consecutive menstrual cycles
, • B. Amenorrhea lasting for 12 consecutive months
• C. Regular menses accompanied by severe hot flashes and night
sweats
• D. Complete cessation of ovarian function prior to age 40
Correct Answer: A. Persistent difference of 7 days or more in the length
of consecutive menstrual cycles
Detailed Rationale: Early perimenopause is characterized by a
persistent difference of 7 days or more in consecutive cycle lengths due
to fluctuating ovarian function.
Question 3
Which hypothalamic neuronal population is primarily responsible for
generating vasomotor symptoms when deprived of estrogen?
• A. Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
• B. Dopaminergic neurons of the substantia nigra
• C. Oxytocin-secreting paraventricular neurons
• D. Serotonergic neurons of the raphe nucleus exclusively
Correct Answer: A. Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
Detailed Rationale: Estrogen withdrawal leads to hypertrophy and
hyperactivation of KNDy neurons in the infundibular nucleus, narrowing
the thermoneutral zone and triggering inappropriate heat dissipation
responses.
Question 4
,For a postmenopausal woman with an intact uterus, what is the clinical
necessity of adding a progestogen when systemic estrogen is
prescribed?
• A. To prevent endometrial hyperplasia and malignancy caused by
unopposed estrogen stimulation
• B. To prevent all-cause mortality and cardiovascular disease
• C. To increase bone mineral density in the cortical skeleton
• D. To eliminate the need for routine lipid panel surveillance
Correct Answer: A. To prevent endometrial hyperplasia and malignancy
caused by unopposed estrogen stimulation
Detailed Rationale: Unopposed systemic estrogen stimulates
unchecked proliferation of the endometrium, which significantly
increases the risk of hyperplasia and endometrial cancer. Progestogen
induces secretory changes that protect the uterine lining.
Question 5
Which of the following conditions represents an absolute
contraindication to the initiation of systemic menopausal hormone
therapy (MHT)?
• A. Active or history of breast cancer
• B. Controlled essential hypertension
• C. Mild asymptomatic cholelithiasis
• D. Stable treated hypothyroidism
Correct Answer: A. Active or history of breast cancer
, Detailed Rationale: Estrogen-sensitive malignancies, such as breast
cancer, represent absolute contraindications to systemic MHT because
exogenous hormones can stimulate tumor growth or recurrence.
Question 6
Which non-hormonal medication class is commonly utilized as a first-
line therapy for moderate-to-severe vasomotor symptoms when
hormone therapy is contraindicated or declined?
• A. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-
norepinephrine reuptake inhibitors (SNRIs)
• B. Loop and thiazide diuretics
• C. Proton pump inhibitors
• D. H2-receptor antagonists
Correct Answer: A. Selective serotonin reuptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs)
Detailed Rationale: Low-dose SSRIs and SNRIs modulate central
neurotransmitter tone and help reset the thermoneutral zone,
providing safe and effective non-hormonal relief for hot flashes.
Question 7
What clinical term describes the collection of symptoms including
vaginal dryness, dyspareunia, burning, and urinary urgency experienced
during and after the menopausal transition?
• A. Genitourinary syndrome of menopause (GSM)
• B. Premature ovarian insufficiency (POI)
• C. Polycystic ovary syndrome (PCOS)
